Editorial Policies
- Aims and Scope
- Publication types
- Peer Review Process
- Publication Frequency
- Open Access Policy
- Archiving
- Author Self-Archiving
- Indexation
- Publication Ethics
- Attribution of authorship
- Disclosure of Potential Conflicts of Interest
- Confidentiality and personal data
- Data sharing policy
- Advertisement and reprint policy
- Retraction, Corrections and Fundamental errors in published works
- Appeal
- Manuscript withdrawal
- Publication Fees
- Marketing
Aims and Scope
The aim of the journal is to provide health care professionals with the latest results of scientific research, practical and innovative activities focused on modernisation and development of priority areas for the development, testing and implementation of new scientific and technological processes in medicine.
Objectives:
- Professional coverage of contemporary developments in the sphere of scientific research policy and policy of innovation and commercialization of scientific research.
- Communication of results of the leading strategic areas: digital medicine, neuroscience, biotechnology, biomarker-controlled therapy with respect to shaping advanced scientific knowledge relying on international expertise of academic community.
- Integration of results of scientific research by Russian specialists into the international scientific environment on the advanced frontiers of development of international medical science.
- Focus of attention on prospective areas of medicine development with regard to implementation of the technological sector of economy “Informational technology in healthcare”.
- Assistance to medical professionals in mastering advanced technology in diagnostics, treatment and prevention of a wide range of diseases using complex laboratories to form interdisciplinary big data, complex systems and artificial intelligence, world-class omics technologies, and implementation of smart medical decision-making support systems based on patient’s digital twins.
- Assistance in efficiency of implementation of results of scientific research in practical healthcare based on the use of products of the innovative territorial cluster of medical and pharmaceutical technology.
Types of Publications
The journal publishes original study articles, narrative and systematic reviews, as well as meta-analyses on current topics, being of interest to a wide range of readers and based on a critical analysis of modern literature sources. We publish rare clinical cases with discussions in order to improve the skills of practitioners. We accept short articles for anniversaries and memorials, as well as information and reports on research and practice conferences and symposia.
Publication types
Original study articles
The journal accept manuscript containing results of international and local clinical and experimental studies, and meta-analyzes.
The journal is welcome for manuscripts with human subjects studies results, as well as results of experimental studies in vitro and animal studies.
Editorial board will select for publication only manuscropts of clinical and experimental studies which were conducted in accordance with international biomedical ethics and deontology principles. Editorial board asks the authors to describe that presented study was conducted in accordance with international GCP standards: voluntary signing of an informed consent by all of participants; approval of the study protocol by the local ethics committee (the distinct name of ethics committee, the meeting date and protocol number should be indicate in a manuscript), etc.
The detailed study protocol should be presented in the manuscript. Authors should give so many details of a study protocol as need for it fully replaying. In the case of meta-analyze authors should describe in details the procedure of information search: names of databases, filters and keywords, as well as any additional search settings for primary sources collecting.
In compliance with the ethics policy editorial board asks authors to indicate the source of funding of their work (study preparation, writing and publishing the manuscript, etc.), and declare of apparent or potential conflicts of interests. Please note that the presence of obvious or potential conflict of interest (including the financial interest of the authors) or affiliation of any organization (public or private) with conduction of the research is not a reason for a manuscript rejection. Rather, it gives additional advantages of manuscript under evaluation by reviewers and will cause more interest and trust from readers.
Reviews
The journal publishes narrative reviews and systematic reviews of clinical trials in different directions of medicine.
The main purpose of a review manuscript should be a discussion of actual data or presentation the original author's view on a problem. It shouldn't be a simple enumeration of previously published data. Thus, the discussion is a mandatory part of the review manuscript (it can be isolated in a separate section or place systematically throughout the text).
Authors should indicate all the sources of primary information in the manuscript (names of the full-text and references databases, keywords and other search settings).
The manuscript of literature review should be structured into sections and contain graphic materials.
Short communications and clinical case reports
The journal is looking for manuscripts with case reports in the area of clinical and experimental medicine.
Potential topics for case reports are:
- diagnosis - new or rare diabetes-related condition or unusual presentation of common condition, uncertain diagnosis situation, discussion of differential diagnoses, novel diagnostic procedures;
- treatment - new treatments or established treatments in new situations, treatment of rare diabetes-related conditions, unique technical procedures, unexpected outcomes or effects from routine or rare procedures, adverse events or unanticipated events;
- special circumstances - highly individualized treatments, complex situations, integration of multiple therapies, ethical challenges, learning from errors, findings that shed new light on the possible pathogenesis of a disease or an adverse effect.
The main purpose of a manuscript should be a clinical case presentation in view of diagnostic approach, ethical or management challenge, or highlights new aspects of pathogenesis, pharmacology or histopathology. Manuscript should discuss accumulated facts and also compare new data with previously proven information.
We recommend all authors to hold the manuscript structure and chronologize all the facts, report common information about the patient’s disease. In case your manuscript is devoted to treatment challenge, describe the medication, its indications and usage specifications also with any potential side effects. A summary of data on the topic may be also presented. Briefly summarize the background of this case report. Describe the patient characteristics (such as the relevant demographics — age, gender, ethnicity, occupation) and their presenting concerns with relevant details of related past interventions. Also, present the medical, family, and psychosocial history including lifestyle and genetic information, other pertinent co-morbidities and interventions (other therapies including self-care).
Data structure for a case report should include the following sections:
- symptoms of the disorder;
- physical examination focused on the important findings including results from testing;
- diagnostic methods (including laboratory testing, imaging results, questionnaires, referral diagnostic information);
- diagnostic challenges (such as limited ability to complete an evaluation, patient availability, cultural) and diagnostic reasoning including other diagnoses considered;
- interventions (such as pharmacologic, surgical, preventive, lifestyle, self-care);
- administration and intensity of the intervention (including dosage, strength, duration, frequency);
- prognostic characteristics.
Please describe the strengths and limitations of this case report including case management, and the scientific and medical literature related to this case report. Discuss the rationale for your conclusions such as potential causation and the ways this case might be generalized to a larger population. Finally, what are the main findings of this case report and what are the 'take-away' messages?
Peer Review Process
Editorial assessment and peer review
All scientific articles submitted to the editorial board of the journal "Science and Innovations in Medicine" undergo a mandatory Editorial assessment and peer review.
- Editorial assessment is performed by the scientific editor (if necessary – by the editor-in-chief, deputy editors-in-chief, head of the editorial office). The editor checks the compliance of the manuscript with the journal's subject area and the requirements for the article design. At this point, the editorial board may reject the article without reason explained, as well as return the manuscript for the author's revision.
- A manuscript that has successfully passed editorial assessment is sent for external peer review to at least two
- The peer-review process involves external experts – leading Russian and international specialists in the relevant field of medicine. The members of the editorial board may also be invited for peer-review. The choice of peer-reviewers is the privilege of the editorial board.
- The peer-reviewers are qualified experts in the field of peer-reviewed manuscript having publications on the subject of the peer-reviewed article not older than three years.
- Peer-review is double anonymized ("double-blinded" — peer-reviewer doesn't know the identity of the author, and vice-versa).
- The editorial board, having received a peer-reviewer's report on the manuscript, obligatory sends a copy of the report to the author.
- A positive peer-review report is not an absolute basis for the publication of the manuscript. A negative peer-review is also not an unconditional reason for refusing publication. The final decision on the publication of the article is a collegiate decision of the editorial board. The article not recommended for publication by the decision of the editorial board is not accepted for reconsideration.
- If case of disagreement between the author and the peer-reviewer, the editorial board has the right to send the manuscript for additional peer-review.
- Each manuscript can have maximum three rounds of peer-review. Manuscript will be rejected if the majority of peer-reviewers will have significant remarks after three rounds of manuscript revision.
- The editorial board obligatory informs the author about its decision on the article (acceptance for publication, rejection, referral for revision) by sending an appropriate notification.
- The peer-reviewer's reports are subject for archiving during 5 (five) years by the editorial office.
- Peer-review reports are kept out of public domain. They are used only in the internal workflow of the editorial office and communication with authors. Copies of the peer-reviewers’ reports can be provided to the Ministry of Science and Higher Education of the Russian Federation upon request.
Peer-Review process
- Peer-Reviewers use a special form. Different forms of review report are to be used for different publication types.
- The standart peer-review time is 3 to 4 weeks (it can be extended at the request of the peer-reviewer).
- After the manuscript is peer-reviewed, the peer-reviewer gives one of the following recommendations:
- the article is recommended for publication without correction;
- the article is recommended for publication after minor correction;
- the article needs substantial revision;
- the article cannot be published.
- A peer-reviewer has the right to refuse invitation to peer-reviewing a manuscript if there is an obvious conflict of interest, which affects the perception and interpretation of the manuscript content.
Author's activity
- The author(s), who has received a recommendation to make corrections from the editorial board, is obliged to submit a revised version of the manuscript within 3 months from the date of sending the corresponding request. Otherwise, if the mentioned period for article revision has expired, the article is de-listed from further consideration and peer-review.
- The author, having received the editorial board's recommendation for article revision after peer-review and the reviewer(s) report(s), should consider the peer-reviewer's comments when preparing a new version of the article. The author should provide answers to all questions, comments and suggestions presented by the peer-reviewer. In case of disagreement with the comments of the peer-reviewers, the author should convincingly argue his/her point of view.
A new (reviced) version of the article should be submitted to the editorial office within 3 months from the date of sending the peer-review report to the author. The article revised by the author is sent for re-evaluation. - The author has the right to refuse to finalize the manuscript. In this case, he/she must notify the editorial board in written form on the decision to withdraw the article from peer-review.
If the author does not return the revised version after 3 months from the date of sending the peer-review report, the manuscript is automatically considered withdrawn by the author from further processing. The author is duly notified on this.
Support for reviewers
The editorial board of the journal "Science and Innovations in Medicine" believes that peer-reviewers play a key role in the existence, successful development and promotion of the journal. Cooperating with our journal exclusively on a voluntary and gratuitous basis, it is the peer-reviewers who largely determine the scientific component of the published content.
Trusting our peer-reviewers as experienced and responsible experts in the relevant scientific fields, we are also interested in publishing their copyrighted materials. Moreover, the manuscripts authored by peer-reviewers of our journal undergo a special assessment procedure. The following rules are applied by the editorial board for such manuscripts:
- The decision on publication is made on the basis of one positive peer-review report from an independent expert.
- In case of a positive peer-review report, the manuscript is published in the next nearest issue of the journal out of the general queue.
Publication Frequency
Regular issues publish quarterly, 4 times a year.
Open Access Policy
“Science and Innovation in Medicine” is an open access journal. All articles are made freely available to readers immediatly upon publication.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition - it means that articles have free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself.
For more information please read BOAI statement.
This journal's articles are licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) which allows users to read, copy, distribute and make derivative works for any purposes from the material, as long as the author of the original work is cited properly.
Archiving
The journal uses the PKP Preservation Network (PKP PN) to digitally preserve all the published articles. The PKP PN is a part of LOCKSS (Lots of Copies Keep Stuff Safe) program offers decentralized and distributed preservation, seamless perpetual access, and preservation of the authentic original version of the content.
Also, the journal makes full-text archives on the Russian Science Electronic Library (http://elibrary.ru/) platform.
The journal makes archives in Portico for compliance with the MEDLINE preservation requirement for electronic journals. Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections.
Indexation
The Science and Innovations in Medicine Journal is included into the “List of leading scientific journals under review, where principal data of applicants for scientific degree has to be published”, as decreed by State Commission for Academic Degrees and Titles and revised in 2019.
The journal is indexed in the following international databases and directory editions:
- Russian Science Citation Index (elibrary.ru)
- DOAJ
- Google Scholar
- Ulrich's Periodical Directory
- Dimensions
- Crossref
Publication Ethics
The "Science and Innovation in Medicine" journal publishes articles that comply with international norms of publication ethics in scientific journals. A manuscript will be withdrawn from publication if at any stage of evaluation, editing and pre-publication preparation, or after publication, if the editors or readers identify a violation from the requirements of publication ethics. Withdrawal of the article will also result in a lack of opportunity for the authors team to publish in our journal in the future.
The Ethic policy of "Science and Innovation in Medicine" journal is based on recomendations from international commettees:
- RASEP — Russian Association of Science Editors and Publishers https://rassep.ru/
- ICMJE — The International Committee of MEDICAL JOURNAL EDITORS http://www.icmje.org/
- WAME — The WORLD ASSOCIATION OF MEDICAL EDITORS http://www.wame.org/
- COPE — Committee on Publication Ethics http://publicationethics.org/
- ORI — The office of Research Integrity http://ori.hhs.gov/
- CSE — Council of Science Editors http://www.councilscienceeditors.org/
- EASE — European Association of Science Editors http://www.ease.org.uk/
Reporting standarts
The "Science and Innovation in Medicine" journal editorial team ask authors of reports of original research to present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.
Review and professional publication articles should also be accurate and objective, and editorial opinion works should be clearly identified as such.
Data Access and Retention
Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.
Authorship clarified
The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before the work is submitted.
The Publisher does not prescribe the kinds of contributions that warrant authorship. It is recommended that authors adhere to the guidelines for authorship that are applicable in their specific research field. In absence of specific guidelines it is recommended to adhere to the following guidelines (based on ICMJE guidelines):
All authors whose names appear on the submission:
- made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work AND;
- drafted the work or revised it critically for important intellectual content AND;
- approved the version to be published AND;
- agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Anyone who contributed to the research or manuscript preparation, but is not an author, should be acknowledged with their permission.
Submissions by anyone other than one of the authors will not be considered.
Research Ethics and Patient Consent (Statement of Human and Animal Rights)
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
Hazards for Human or Animal Subjects
If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the authors should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
When reporting experiments on animals, authors have to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.
Research involving human embryos, gametes, and stem cells
Manuscripts that report experiments involving the use of human embryos and gametes, human embryonic stem cells and related materials, and clinical applications of stem cells must include confirmation that all experiments were performed in accordance with relevant guidelines and regulations (See also Research involving human participants and/or animals)
The manuscript should include an ethics statement identifying the institutional and/or national research ethics committee (including the name of the ethics committee) approving the experiments and describing any relevant details. Authors should confirm that informed consent (See also Informed consent) was obtained from all recipients and/or donors of cells or tissues, where necessary, and describe the conditions of donation of materials for research, such as human embryos or gametes. Copies of approval and redacted consent documents may be requested by the Journal.
We encourage authors to follow the principles laid out in the 2016 ISSCR Guidelines for Stem Cell Research and Clinical Translation.
In deciding whether to publish papers describing modifications of the human germline, the Journal is guided by safety considerations, compliance with applicable regulations, as well as the status of the societal debate on the implications of such modifications for future generations. In case of concerns regarding a particular type of study the Journal may seek the advice from the Springer Nature Research Integrity Group.
The decision to publish a paper is the responsibility of the Editor-in-Chief of the Journal.
Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout.
Conflicts of Interest
The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.
Conflicts include the following:
- Financial — funding and other payments, goods and services received or expected by the authors relating to the subject of the work or from an organization with an interest in the outcome of the work;
- Affiliations — being employed by, on the advisory board for, or a member of an organization with an interest in the outcome of the work;
- Intellectual property — patents or trademarks owned by someone or their organization;
- Personal — friends, family, relationships, and other close personal connections;
- Ideology — beliefs or activism, for example, political or religious, relevant to the work;
- Academic — competitors or someone whose work is critiqued.
For more information on conflicts of interest, see the guidance from the ICMJE and WAME.
Funding and Acknowledgement of Sources
Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/
Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.
Plagiarism
Plagiarism takes many forms, from passing off another paper as the author(s) own paper, to copying or paraphrasing substantial parts of another(s) paper (without attribution), to claiming results from research conducted by others.
Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Only original works are acceptable for publication in "Science and Innovation in Medicine" journal.
The journal does not allow any forms of plagiarism. Authors must not use the words, figures, or ideas of others without attribution. All sources must be cited at "Science and Innovation in Medicine" journal take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously.
We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. All the submitted articles are evaluated with plagiarism-checking software (Antiplagiat).
Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgment, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to:
- publishing an erratum or corrigendum (correction);
- retracting the article;
- taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies;
- or taking appropriate legal action.
Also you can see ORI Avoiding Plagiarism, Self-plagiarism, and Other Questionable Writing Practices: A Guide to Ethical Writing
Identification of illegal borrowings is carried out as part of scientific peer-review through the ANTI-PLAGIARISM system (Antiplagiat).
At this stage of evaluation:
- The editors do not take into account the percentage of originality calculated by the anti-plagiarism program;
- The editors relies only on an expert analysis of the full report of the program;
- The editors allow for complete coincidence in the description of the applied research methods with such in previously published articles, textbooks, manuals.
The editors believe that the introduction, results, discussion and conclusion (conclusions) should be completely original.
If conclusions coincide with those formulated earlier by other researchers, this should be explicitly indicated in the manuscript in the discussion section.
Duplicate Submission and Redundant Publication
"Science and Innovation in Medicine" journal consider only original content, i.e. articles that have not been previously published, including in a language other than English. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered.
Manuscripts submitted to "Science and Innovation in Medicine" journal must not be submitted elsewhere while under consideration and must be withdrawn before being submitted elsewhere. Authors whose articles are found to have been simultaneously submitted elsewhere may incur sanctions.
If authors have used their own previously published work, or work that is currently under review, as the basis for a submitted manuscript, they must cite the previous articles and indicate how their submitted manuscript differs from their previous work. Reuse of the authors’ own words outside the Methods should be attributed or quoted in the text. Reuse of the authors’ own figures or substantial amounts of wording may require permission from the copyright holder and the authors are responsible for obtaining this.
"Science and Innovation in Medicine" journal will consider extended versions of articles published at conferences provided this is declared in the cover letter, the previous version is clearly cited and discussed, there is significant new content, and any necessary permissions are obtained.
Redundant publication, the inappropriate division of study outcomes into more than one article (also known as salami slicing), may result in rejection or a request to merge submitted manuscripts, and the correction of published articles. Duplicate publication of the same, or a very similar, article may result in the retraction of the later article and the authors may incur sanctions.
Citation Manipulation
Authors whose submitted manuscripts are found to include citations whose primary purpose is to increase the number of citations to a given author’s work, or to articles published in a particular journal, may incur sanctions.
Editors and reviewers must not ask authors to include references merely to increase citations to their own or an associate’s work, to the journal, or to another journal they are associated with.
Fundamental errors in published works, Corrections and Retractions
When an author discovers a significant error or inaccuracy in his/her own published work, it is the authors obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper.
If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.
When errors are identified in published articles, the publisher will consider what action is required and may consult the editors and the authors’ institution(s).
Errors by the authors may be corrected by a corrigendum, and errors by the publisher — by an erratum.
If there are errors that significantly affect the conclusions or there is evidence of misconduct, this may require retraction or an expression of concern following the COPE Retraction Guidelines. All authors will be asked to agree to the content of the appropriate notice.
Sanctions
If "Science and Innovation in Medicine" journal becomes aware of breaches of our publication ethics policies, the following sanctions may be applied:
- Rejection of the manuscript and any other manuscripts submitted by the author(s).
- Not allowing submission for 1–3 years.
- Prohibition from acting as an editor or reviewer.
"Science and Innovation in Medicine" journal may apply additional sanctions for severe ethical violations.
Attribution of authorship
Editorial board emphasize that only those persons who have made a significant contribution to the conception of the work, the development, execution, and/or interpretation of the results of the presented study, as well as to the process of writing the manuscript (including scientific and stylistic editing and design in accordance with the requirements of the journal) may be recognized as the Authors of the publication.
When submitting a manuscript to the journal, Authors shall ensure that:
- All participants who made a significant contribution to the reported study are presented as Co-Authors;
- Those who did not participate in the study are not listed as Co-Authors;
- All Co-Authors have read and approved the final version of the paper and agreed to its submission for publication—this shall be confirmed by the signatures of all Authors in the cover letter.
Disclosure of Potential Conflicts of Interest
All Authors must disclose in their manuscript ― declare in the appropriate section of the manuscript ― any financial or other relevant interests that might be construed to influence the findings or interpretation of their research.
Examples of potential conflicts of interest to be disclosed are given below:
- Receiving financial rewards for participating in the research or writing of a manuscript;
- Any affiliation (contract work, consulting, equity assets, fees, and expert opinions) with organizations that have a direct interest in the subject matter of the research or review;
- A patent application or registration for research findings (copyright, etc.);
- Receiving financial support for any of the stages of conducting the research or writing a manuscript (including grants and other forms of financial support).
Information on conflicts of interest received from the Authors of manuscripts should be available only to the Editorial Board when deciding whether to publish the manuscript. Such information on conflicts of interest shall then be published as part of the full text of the paper.
When writing this part of the manuscript, the Publisher recommends using the interactive form available at https://admin1.journals.elsevier.com/media/bpwkqcoc/coi_disclosure.pdf
A Reviewer shall not participate in the review of manuscripts if there are conflicts of interest due to competitive, collaborative, and other interactions and relationships with any of the Authors, companies, or other organizations related to the submitted paper.
Editors recuse themselves from reviewing manuscripts if there are conflicts of interest due to competitive, collaborative, and other interactions and relationships with Authors, companies, and possibly other organizations related to the manuscript.
Confidentiality and personal data
The Editor and the Editorial Board shall not unnecessarily disclose information on the manuscript under consideration to anyone other than the Authors, Reviewers, possible Reviewers, other Academic Advisors, and the Publisher.
The Editor shall not use unpublished materials disclosed in the submitted manuscript in the Editor’s own research without the written consent of the Author.
Reviewers shall not use unpublished materials from the submitted manuscripts in the Reviewer’s own research without the written consent of the Author.
Reviewers must keep information or ideas obtained during the review process confidential and not use them for personal gain.
Reviewers shall not discuss the manuscript with any person not authorized by the Editor.
Identifiable (personal) information, including patient names and initials or hospital numbers, shall not be published in written descriptions, photographs, and genetic pedigrees unless the information is of great scientific or historical value and the patient (or parent or guardian) gives written consent for its publication.
Ethical guidelines for handling personal data in biomedical research involving human subjects must comply with legal acts, such as the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines for Health-Related Research Involving Humans (2016) ― in particular, Guideline No. 12 “Collection, Storage and Use of Data in Health-Related Research” ― as well as the Russian Federal Law on Personal Data (No. 152-FZ), implemented on July 27, 2006.
Data sharing policy
Authors are encouraged to make the research data that support their publications available but are not required to do so. The decision to publish will not be affected by whether or not authors share their research data.
Definition of research data
This policy applies to the research data that would be required to verify the results of research reported in articles published in the journal “Science and Innovations in Medicine”. Research data include data produced by the authors (“primary data”) and data from other sources that are analysed by authors in their study (“secondary data”). Research data includes any recorded factual material that are used to produce the results in digital and non-digital form. This includes tabular data, code, images, audio, documents, video, maps, raw and/or processed data.
Definition of exceptions
The data that is not a subject to public disclosure may be delivered as follows: deposited in science data repositories with limited access or preliminary anonymised. An author can also publicly deliver metadata only and/or description of the method of access to the data under requests from other scholars.
Data repositories
The preferred mechanism for sharing research data is via data repositories. Please see or https://repositoryfinder.datacite.org/ for help finding research data repositories.
Data citation
The Editorial Board of the Journal “Science and Innovations in Medicine” welcomes access to data under Creative Commons Licenses. Editorial Board of the Journal “Science and Innovations in Medicine” does not insist on the obligatory use of Creative Commons in case when the data is deposited in the repositories of the third party. The Publisher of the Journal “Science and Innovations in Medicine” does not assert any copyrights for the data submitted by the author together with the article.
Advertisement and reprint policy
The journal's advertising policy complies with the Recommendations on Publication Ethics Policies for Medical Journals issued by the World Association of Medical Editors (WAME). http://www.wame.org/recommendations-on-publication-ethics-policie
- All advertisements are subject to the approval of the journal's management team.
- The journal's management team has the right to reject any advertising which, in the opinion of the editors, is incompatible with the mission of the journal or does not meet its objectives, and to stop the publication of any previously approved advertising. No separate agreements can override this rule.
- The advertising content must be distinguished from editorial and other materials to make the difference between them obvious for the readers.
- The journal does not publish advertorials. Sponsored supplements must be clearly indicated as such. If a supplement has not passed the peer review or was subjected to a peer review process different from that of the journal, that should be explicitly stated.
- Once an advertisement has been published online, it can be withdrawn from the journal web-site at any time if the journal's management requests its removal.
- Advertising for the following categories is prohibited:
- Alcohol
- Tobacco
- Weapons, firearms, ammunition
- Fireworks
- Gambling and lottery
- Pornography or related themes
- Political and religious advertisements
- Advertisements that claim to have a “miracle” cure or method
- Advertisements that make unsubstantiated health claims for the products advertised
- Advertisements directed at children.
- Advertisements may not be deceptive or misleading, and must be verifiable. Advertisements should clearly identify the advertiser and the product or service being offered. Exaggerated, sense distorting or extravagantly worded statements will not be allowed. Advertisements will not be accepted if they appear to be indecent or offensive in either text or artwork, or if they relate to content of a personal, racial, ethnic, sexual orientation, or religious nature.
- All advertisements are accepted and published on the warranty of the advertisement agency and advertiser that both are authorized to publish the entire contents and subject matter of the advertisement.
- In consideration of publication of an advertisement, the advertiser and the advertisement agency, jointly and severally, agree to indemnify and hold harmless the journal, its officers, agents and employees against expenses (including legal fees) and losses resulting from the publication of the contents of the advertisement, including, without limitation, claims or suits for libel, violation of privacy, copyright infringement, or plagiarism.
- Any references to our journal or its products or services in advertisements, promotional material, or merchandising by the advertiser or agency is subject to journal 's management written approval for such use.
- All advertisements for drug-specific and medical services campaigns must comply with the relevant Russian legislation that regulates advertising. Advertisers should make available to the editorial board the marketing authorization and summary of product characteristics when submitting their advertisement. In the case of drug advertisements, proprietary names of pharmaceutical products must be accompanied by the chemical, generic, or official name; the quantity of all active substances must be stated along with the recommended dosage. Each page of an advertisement for a prescription-only medicine should be clearly labeled as intended for health professionals.
- Advertisements for products not approved by the Ministry of Health of the Russian Federation that make any kind of health claims must carry the following disclaimer: “These statements have not been evaluated by the Ministry of Health of the Russian Federation. This product is not intended to diagnose, treat, cure or prevent any disease.”
- Our journal welcomes and encourages information and data-rich advertising, but advertisements should not resemble scientific publications; advertising icons and advertiser logos must be clearly distinguishable from editorial content and may require special labeling to distinguish them as such. All advertisements must clearly and prominently identify the advertiser by trademark or signature.
- Reprints should be published only in the form in which they were originally published in the journal (including subsequent corrections), so there should be no additions or changes in them.
- The journal's editors is not responsible for incidental or consequential damage for errors in displaying or printing an advertisement.
- Publishing of an advertisement does not imply journal sponsorship or influence on its authors, publications, peer review process or perspectives of publishing an article in the journal/on the web site for the advertiser’s part.
- The full rules for any market research or promotion associated with an advertisement must be displayed in the advertisement or available via a prominent link.
- The following online advertising formats are prohibited:
- Pop-ups and floating advertisements.
- Advertisements that collect personally identifiable information from visitors without their knowledge or permission.
- Advertisements that extend across or down the page without the visitor having clicked or rolled-over the advertisement.
- Advertisements that send visitors to another site without the visitor having clicked the advertisement.
Advertising policies are not exhaustive and are subject to change at any time without notice.
Retraction, Corrections and Fundamental errors in published works
Research Data Integrity
Samara State Medical University is committed to uphold the integrity of the literature and publishes Errata (Corrections), Expressions of Concerns or Retraction Notices dependent on the situation and in accordance with the COPE Retraction Guidelines. In all cases, these notices are linked to the original article.
When an author discovers a significant error or inaccuracy in his/her own published work, it is the authors obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper.
If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.
When errors are identified in published articles, the publisher will consider what action is required and may consult the editors and the authors’ institution(s).
Errors by the authors may be corrected by a corrigendum, and errors by the publisher — by an erratum. If there are errors that significantly affect the conclusions or there is evidence of misconduct, this may require retraction or an expression of concern following the COPE Retraction Guidelines. All authors will be asked to agree to the content of the appropriate notice.
The editorial board notifies readers about changes in previously published articles by publishing relevant messages in the upcoming regular issues, as well as by participating in the CrossMark project. More details can be found here: https://doi.org/10.35693/crossmarkpolicy2023
Retraction
Retraction of an already published paper is a measure of last resort and is applied in case facts are revealed that were not known during the reviewing process.
According to the rules of the Council on Ethics of Scientific Publications of Association of Science Editors and Publishers, the grounds for article retraction are:
- detection of plagiarism in the article;
- detection of falsifications (for example, manipulation of experimental data);
- detection of serious errors that cast doubt on scientific value of the article;
- incorrect list of authors;
- duplication of the article in several journals;
- republishing the article without the author’s consent;
- concealment of conflict of interest and other violations of publication ethics;
- the fact that the article hasn’t been peer reviewed.
After the decision to retract the article is made, the editor-in-chief informs its authors, indicating the reason and date of retraction. The article remains on the journal’s site as part of the corresponding journal issue, but is marked “retracted” with the retraction date (the mark is placed on top of the text of the article and in the table of contents); in addition, a message about retraction is placed in the news section of the site, and the chief editor sends information about the article retraction to all online libraries and databases in which the journal is indexed.
Information on COPE Retraction Guidelines can be found here: Retraction Guidelines
Retraction Mechanism
Authors, Readers, Reviewers, Editors, and Publishers may initiate the retraction of a paper by writing to the Editorial Board of the journal in which the paper was published.
The Retraction Commission shall consider the appeal and notify the parties concerned of the initiation of the procedure.
The Retraction Commission shall decide to retract the published paper if there are sufficient facts in favor of its retraction.
The Retraction Commission shall notify the initiator of the retraction about the results in writing.
If the Commission decides to retract a paper, the journal shall publish information that the paper has been retracted with an indication of its metadata.
If papers from the journal are indexed by any databases, a letter shall be sent to these databases that the paper was retracted with the reasons for the retraction.
- The Editorial Board shall be free to make its own decisions on additional sanctions, such as adding the Authors to the journal’s “blacklist” for a certain or indefinite period.
Appeal
The decision to reject the manuscript is final and is not subject to appeal.
Manuscript withdrawal
Authors can withdraw their manuscript at any stage of consideration and preparation for publication.
Withdrawal procedure
- The author's team sends a letter to e-mail of the editorial office with a request to withdraw the manuscript from consideration or publication, indicating the reason. The letter must contain a scanned appeal of the author's team with the signatures of all co-authors (PDF).
- The editorial board notifies the authors of the receipt of the letter.
- Within a week, the Editorial Board notifies the authors of the withdrawal of the manuscript from consideration or the termination of its preparation for publication and moves the manuscript to the electronic archive by means of the editorial and publishing platform.
- If the authors have not received a response from the editorial board within a week, then you should contact the publisher or the editor-in-chief of the journal, attaching the correspondence.
- If, despite sending messages to the editorial office, the publisher and the editor-in-chief, the article being withdrawn was published in the journal, the withdrawal of the manuscript is possible only through the retraction procedure (see Retraction).
Publication Fees
Publication in Science and Innovations in Medicine journal is free for all authors.
The Science and Innovations in Medicine journal charge no publication fees for authors - including those of peer-review management, manuscript processing, journal production, Open-Access, online hosting and archiving.
Marketing
As part of scientific and practical events (conferences, symposiums), participants are provided with a free copy of the journal.
The publisher does not send requests to potential authors to submit manuscripts.
The publisher provides an opportunity for reviewers to submit a review to Publons.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор). Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-65957 от 06 июня 2016 г.